Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
JERSEY, Channel Islands, Feb. 01, 2016 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ending December 31, 2015 will be released before the market opens on Monday, February 8th, 2016.
Quotient will host a conference call on Monday, February 8th at 8:30 a.m. Eastern Time to discuss its third quarter fiscal 2016 financial results. Participants may access the call by dialing 1-877-407-9039 in the U.S. or 1-201-689-8470 outside the U.S. The conference call will be webcast live on the Company's website at www.quotientbd.com.
A replay of this conference call will be available through February 15 by dialing 1-877-870-5176 in the U.S. or 1-858-384-5517 outside the U.S. The replay access code is 13629523.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
CONTACT: Stephen Unger, Chief Financial Officer – [email protected]; (212) 228-7572
